Ameriprise Financial Inc. Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Ameriprise Financial, Inc. is a diversified financial services firm providing financial planning, products, and services for cash management, asset accumulation, income, protection, and estate planning. As of March 31, 2026, the company reported $1.67 trillion in total assets under management, administration, and advisement.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Net Revenues | $4,812 million | $4,354 million |
| Pretax Income | $1,144 million | $687 million |
| Net Income | $915 million | $583 million |
| Diluted EPS | $9.68 | $5.83 |
| Adjusted Operating Earnings | $1,064 million | $950 million |
| Cash and Cash Equivalents | $8,341 million | $9,953 million |
| Long-Term Debt | $3,079 million | $3,077 million |
| Shareholders' Equity | $6,212 million | $6,549 million |
Adjusted Operating Return on Equity (excluding AOCI): 54.3% (Trailing Twelve Months ended March 31, 2026).
Material Changes vs. Prior Period
- Revenue Growth: Total net revenues increased 11% ($458 million) driven by a 13% rise in management and financial advice fees and an 8% increase in distribution fees, largely due to equity market appreciation and net inflows in wrap accounts.
- Profitability Surge: Pretax income increased 67% ($457 million) and Net Income increased 57% ($332 million). A primary driver was a reduction in the market impact expense on non-traditional long-duration products, which decreased from $460 million in Q1 2025 to $184 million in Q1 2026.
- Expense Management: Total expenses remained flat year-over-year. Distribution expenses rose 10% due to higher advisor compensation, while benefits and claims expenses fell 17% due to favorable market impacts on structured variable annuity embedded derivatives.
- Assets Under Management (AUM): Total AUM grew 11% to $1.28 trillion, with Advice & Wealth Management AUM increasing 16% to $660.6 billion.
Guidance, Outlook, and Risks
Management Commentary: Management highlighted strong performance driven by market appreciation and client net inflows. The company continues to shift its product mix away from variable annuities with living benefit riders to optimize risk. The effective tax rate was 20.0% for the quarter, up from 15.1% in the prior year, primarily due to higher pretax income.
Capital Actions: The company repurchased 1.6 million shares for $784 million during the quarter. As of March 31, 2026, $1.8 billion remained under the $4.5 billion share repurchase authorization. A quarterly dividend of $1.70 per share was declared.
Risks and Contingencies:
- Market Risk: Significant exposure to equity price and interest rate fluctuations. A hypothetical 10% equity price decline would result in a net negative impact of $608 million to pretax income, while a 100 basis point interest rate increase would result in a net positive impact of $493 million.
- Regulatory: The company is subject to ongoing examinations by various regulators (SEC, FINRA, state insurance regulators) regarding sales practices, disclosure, and supervision of financial advisors.
- Reinsurance: The company maintains reinsurance agreements for Long-Term Care (LTC) exposure with Genworth Life Insurance Company (GLIC), with management believing credit protections are robust.
Investor Verification Checklist
- Market Impact Volatility: Verify the sustainability of the reduced market impact expense on non-traditional long-duration products ($184M vs $460M prior year) and its sensitivity to future equity and interest rate movements.
- Asset Flows: Monitor net flows in the Asset Management segment, which experienced outflows of $5.9 billion in Q1 2026, contrasting with inflows in the Advice & Wealth Management segment.
- Interest Rate Sensitivity: Review the duration of the investment portfolio supporting fixed annuity and certificate liabilities against the guaranteed minimum interest rates (GMIRs) to assess spread compression risks.
- Share Repurchase Execution: Track the pace of share repurchases against the remaining $1.8 billion authorization and the impact on diluted share count.
- Regulatory Exposure: Assess the potential financial impact of ongoing regulatory inquiries and litigation mentioned in Note 17 (Contingencies).